drugset / Trial / NCT02014376
Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study was to assess whether the topical use of SD-101 cream (3% or 6%) was effective in treating wounds in participants with Simplex, Recessive Dystrophic, or Junctional non-Herlitz Epidermolysis Bullosa (EB).
Timeline
- Start
- 2014-01-06
- Primary completion
- 2014-06-24
- Completion
- 2014-06-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nelitolimod | Oligonucleotide (other) | 3 % | Topical |
| Subject | Nelitolimod | Oligonucleotide (other) | 6 % | Topical |